Healthcare Global Enterprises Ltd. · NSE:HCG
Healthcare Global Enterprises — Q3 FY2023 Earnings Presentation
23 slides from Healthcare Global Enterprises's earnings presentation, Feb 9, 2023
Slide 1: Investor Presentation cover letter to stock exchanges
February 09, 2023 National Stock Exchange of India Limited, BSE Limited, Compliance Department, Compliance Department, Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai - 400051, Dalal Street, Mumbai - 400001, Maharashtra, India Maharashtra, India Dear Sir/Madam,
Slide 2: Healthcare Global Enterprises Limited Investor Presentation
HEALTHCARE GLOBAL ENTERPRISES LIMITED INV E STOR P R E SE NTAT ION February 2023
Slide 3: Safe Harbor
SAFE HARBOR This presentation and its contents are confidential and are not for release, publication or distribution, in whole or in part, directly or indirectly, in or into or from the United States of America, Canada, Australia, Japan or any jurisdiction where such distribution is unlawful. This p
Slide 4: Q3 & 9MFY23 Financial & Operational Highlights
Q3 & 9MFY23 FINANCIAL & SUBASENI LENKA, CANCER WINNER OPERATIONAL HIGHLIGHTS I am eternally thankful to Dr. Panda and other specialists at HCG Panda Cancer Hospital, as the specialists were able to treat my condition the right way, the first time 3 www.hcgel.com
Slide 5: Clinical Highlights & Recognitions
Clinical Highlights & Recognitions Clinical Highlights Profiled 1,500+ patients with variety of malignancies using targeted deep sequencing for hotspot mutations in 56/152 cancer related genes 2 of our clinicians at the COE in Bangalore have been named in prestigious National Cancer Institute of
Slide 6: Financial Highlights Q3 FY23
Financial Highlights Q3 FY23 REVENUE R E V E N U E - H C G C e n t e r s (1) REVENUE - Milann Centers^ +19% +20% -1% 4,247 4,080 168 167 3,581 3,412 Q3FY22 Q3FY23 Q3FY22 Q3FY23 Q3FY22 Q3FY23 ADJUSTED EBITDA P R O F I T A F T E R TA X 2 P R O F I T A F T E R TA X 2 ADJUSTED EBITDA MARGIN (Pre-IND AS)
Slide 7: Financial Highlights 9M FY23
Financial Highlights 9M FY23 REVENUE R E V E N U E - H C G C e n t e r s (1) REVENUE - Milann Centers^ +21% +22% +9% 12,527 12,022 463 505 10,332 9,869 9MFY22 9MFY23 9MFY22 9MFY23 9MFY22 9MFY23 ADJUSTED EBITDA P R O F I T A F T E R TA X 2 P R O F I T A F T E R TA X 2 ADJUSTED EBITDA MARGIN (Pre-IND
Slide 8: Improved Performance Leading to Profitability
Improved Performance Leading to Profitability 2.2x 4,081 4,200 4247 3,231 3,520 3,581 3,646 Revenue 2,479 2,740 2,981 (INR mn) 1,935 Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 3.9x 300 722 747 755 EBITDA 194 617 619 633 512 (INR mn) 378 394 Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22
Slide 9: Growth Across HCG Centers
Growth Across HCG Centers Matured Centers Emerging Centers^ ~1.5x g r o w t h i n l a s t 8 q u a r t e r s ~2.0x g r o w t h i n l a s t 8 q u a r t e r s +17% +29% REVENUE# 2,979 3,090 3,065 1,015 929 945 2,596 2,628 2,663 826 2,304 2,418 750 785 2,100 693 509 535 Q3FY21 Q4FY21 Q1FY22 Q2FY22 Q3FY2
Slide 10: HCG – Q3FY23 Operational Metrics
HCG – Q3FY23 Operational Metrics # M AT U R E D C E N T E R S EMERGING CENTERS M AT U R E D C E N T E R S TO TA L A O R ( % ) AOR (%) A O R ^* ( % ) ROCE (%) 65.7% 63.2% 71.9% 19.7% 56.9% in Q3FY22 56.2% in Q3FY22 58.7% in Q3FY22 15.7% in FY22 880 bps 700 bps 1,320 bps 400 bps ROCE pre-corporate a l
Slide 11: HCG – Cluster Wise Revenue Break Up
HCG – Cluster Wise Revenue Break Up # C LU ST E R Q3FY23 Q3FY22 Y-o-Y 9MFY23 9MFY22 Y-o-Y K A R N ATA K A 1,395.9 1,246.5 12.0% 4,194.7 3,485.9 20.3% G U J A R AT 1,025.3 856.3 19.7% 3,078.9 2,604.8 18.2% MAHARASHTRA 615.7 557.4 10.5% 1780.6 1,746.5 2.0% EAST INDIA 419.7 312.0 34.5% 1,208.6 867.0 39
Slide 12: Milann – Implementing Strategic Initiatives
Milann – Implementing Strategic Initiatives BENGALURU (5 Centers) Growth Growth Particulars Q3FY23 Q3FY22* 9MFY23 9MFY22* Y-o-Y Y-o-Y New 1,215 796 52.6% 3,979 1,820 118.6% M S Ramaiah Nagar Registrations Shivananda IVF Cycles 460 314 46.5% 1,471 759 93.8% Indiranagar Revenues Whitefield 167 168 -0.
Slide 13: Capital Expenditure & Net Debt
Capital Expenditure & Net Debt C A P I TA L E X P E N D I T U R E ( R s . M n . ) NET DEBT (Rs. Mn.) NET DEBT 31 st Dec 2022 30 th Sep 2022 HCG CENTERS 9MFY23 FY22 Bank Debt (1) 3,488 3,485 Vendor Finance (2) 223 205 Matured Centers 814 458 Other Debt 14 20 Emerging Centers 146 246 Less: Cash & Cash
Slide 14: Platform for Attractive Returns with Efficient Capital Allocation and Asset Light Expansion
Platform for Attractive Returns with Efficient Capital Allocation and Asset Light Expansion Capital efficient ROCE growth driven by breakup from Cancer Centers* expansion in clinical 18-20% Vintage trials and diagnostics Pre-Corp. Post-Corp. Established Ongoing value Centers 25% 20% creation project
Slide 15: Q3 & 9M FY23 Consolidated Profit & Loss Account
Q3 & 9M FY23 Consolidated Profit & Loss Account Profit and Loss (in Rs. Mn.) Q3 FY23 Q3 FY22 Y-o-Y Q2 FY23 Q-o-Q 9M FY23 9M FY22 Y-o-Y Revenues from Operations 4,239 3,572 4,192 12,504 10,309 Income from Govt. Grant 8 8 8 23 23 Total Revenue from Operations 4,247 3,581 18.6% 4,200 1.1% 12,527 10,332
Slide 16: Consolidated Balance Sheet
Consolidated Balance Sheet B alan c e Sh eet - Eq u ity & Liab ili t ie s (in Rs. M n .) Sep -22 M ar c h -22 B alan c e Sh eet - Assets (Rs. M n .) Sep -22 M ar c h -22 E q u ity Sh are Cap ital 1,391 1,390 N on -Cu rren t Assets Oth er E q u ity 7,420 7,313 Prop erty , Plan t An d E q u ip men t 9
Slide 17: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement Cash Flow Statement (in Rs. Mn) Sep-22 Sep-21 Net Profit Before Tax 204 1,330 Adjustments For: Non - Cash Items / Other Investment Or Financial Items 1,380 -163 Operating Profit Before Working Capital Changes 1,585 1,167 Changes In Working Capital -379 -288 Cash Gene
Slide 18: Historical Financial Highlights
HISTORICAL FINANCIAL SHANKAR, CANCER WINNER HIGHLIGHTS The days I was at HCG, I felt like I was sleeping at home. They never stop caring for you. The doctors and nurses are always finding ways to make this difficult journey as comfortable as possible 17 www.hcgel.com
Slide 19: Historical Profit & Loss Account
Historical Profit & Loss Account Profit and Loss (in Rs. Mn.) FY22 FY21 FY20 FY19 CAGR Revenues from Operations 13,948 10,092 10,923 9,760 Income from Govt. Grant 30 43 33 27 Total Revenue from Operations 13,978 10,134 10,956 9,787 13% Costs of Goods Sold 3,549 3,632 3,645 3,581 Employee Cost 2,337
Slide 20: Historical Balance Sheet
Historical Balance Sheet Balance Sheet - Equity & Liabilities (in Rs. Mn.) Mar-22 Mar-21 Mar-20 Mar-19 Equity Share Capital 1,390 1,254 887 879 Other Equity 7,313 5,718 2,926 3,933 Equity Attributable To Equity Holders Of The Company 8,703 6,972 3,813 4,811 Non-Controlling Interests 134 168 385 619
Slide 21: Historical Balance Sheet
Historical Balance Sheet Balance Sheet - Assets (in Rs. Mn.) Mar-22 Mar-21 Mar-20 Mar-19 Non-Current Assets Property, Plant And Equipment 9,315 8,531 9,271 8,026 Capital Work in Progress 217 300 461 1,440 Rights-of-use Assets 4,045 4,114 5,776 0 Goodwill 1,813 963 1,093 1,093 Other Intangible Assets
Slide 22: Historical Cash Flow Statement
Historical Cash Flow Statement Cash Flow Statement (in Rs. Mn) Mar-22 Mar-21 Mar-20 Mar-19 Net Profit Before Tax 878 -2,287 -1,193 -334 Adjustments For: Non - Cash Items / Other Investment Or Financial Items 1,666 3,619 2,988 2,463 Operating Profit Before Working Capital Changes 2,543 1,333 1,795 2,
Slide 23: Thank You
THANK YOU Company: HealthCare Global Enterprises Limited Investor Relation Advisors: Strategic Growth Advisors CIN: L15200KA1998PLC023489 CIN: U74140MH2010PTC204285 For updates and specific queries, please visit Mr. Sagar Shroff / Mr. Deven Dhruva www.hcgoncology.com sagar.shroff@sgapl.net / deven.d
HealthCare Global Enterprises — Q3 FY2023 Earnings Presentation on 6ix